Role of Recombinant Human Erythropoietin in Neonates with Moderate to Severe Hypoxic Ischemic Encephalopathy - A Prospective Cohort Study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Prospective cohort study shows rhEPO improves EEG and other outcomes in neonates with HIE, suggesting neuroprotective roles.

Administering rhEPO significantly reduced abnormal resistive index rates in neonates with HIE.
The control group had higher instances of severe brain injury compared to the rhEPO group, highlighting treatment benefits.
Improvements in electroencephalogram patterns were noted in neonates treated with rhEPO compared to controls.
Prospective cohort methodology allows for assessment of rhEPO's safety, demonstrating its practical application in clinical settings.

Nagaraju et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark